Off-label use of rituximab in dermatology: pemphigus treatment
Authors:
Open Access
- 1 August 2013
- journal article
- case report
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 88 (4) , 676-678
Abstract
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.Keywords
This publication has 7 references indexed in Scilit:
- Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus VulgarisDermatology Research and Practice, 2010
- Rituximab: a review of dermatological applications.2009
- Treatment of refractory pemphigus erythematosus with rituximabInternational Journal of Dermatology, 2008
- The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.2007
- Treatment of Severe Pemphigus With RituximabArchives of Dermatology, 2007
- Off-label uses of rituximab in dermatologyDermatologic Therapy, 2007
- Rituximab: Applications in dermatologyInternational Journal of Dermatology, 2006